CSPC Pharmaceutical Group Limited — Earnings Release 2000

Apr 19, 2001

Listed Company Information

CHINA PHARMA<1093> - Results Announcement China Pharmaceutical Enterprise and Investment Corporation Limited announced on 19/4/2001: (stock codes: Ord: 1093 & War: 837) Year end date: 31/12/2000 Currency: HKD (Audited) (Audited) Last Current Corresponding Period Period from 1/1/2000 from 1/1/1999 to 31/12/2000 to 31/12/1999 Turnover : 995,096,000 821,321,000 Profit/(Loss) from Operations : 128,639,000 166,751,000 Finance cost : (29,843,000) (29,407,000) Share of Profit/(Loss) of Associates : (290,000) - Share of Profit/(Loss) of Jointly Controlled Entities : 3,779,000 7,210,000 Profit/(Loss) after Tax & MI : 80,473,000 142,022,000 % Change over Last Period : -43% EPS/(LPS)-Basic : 6.49 cents 12.52 cents -Diluted : 6.40 cents 12.41 cents Extraordinary (ETD) Gain/(Loss) : - - Profit/(Loss) after ETD Items : 80,473,000 142,022,000 Final Dividend per Share : Nil 3.3 cents (Specify if with other options) : - - B/C Dates for Final Dividend : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for Current Period : - B/C Dates for Other Distribution : N/A Remarks: 1. Earnings per share The calculation of the basic and diluted earnings per share is based on the following data: 2000 1999 Profit attributable to shareholders HK$80,473,000 HK$142,022,000 ============== ============== Weighted average number of ordinary shares for the purposes of basic earnings per share 1,240,429,301 1,134,591,763 Effect of dilutive potential ordinary shares in respect of share option 16,000,000 9,560,976 -------------- ------------- Weighted average number of ordinary shares for the purposes of diluted earnings per share 1,256,429,301 1,144,152,739 ============= ============== The computation of diluted earnings per share does not assume the exercise of the Company's outstanding warrants as the exercise price is higher than the fair value per share during the year. 2. Comparative figures Certain comparative figures have been reclassified to conform with the current year's presentation.